Wire · opportunities
FDA Approval Might Shift The Case For Scholar Rock Stock (SRRK)
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 September 2026 · Fusion42 review
The FDA approved ISEMBYLD (apitegromab mstn) for treating spinal muscular atrophy in patients aged 2 and older on SMN2 therapies, enabling Scholar Rock Holding to shift from development risk to commercial execution with potential revenues up to $482 million by 2029.
This Wire brief sits within Fusion42's coverage of Biotech, and 11 sources have reported it between 12 Sep 2026 and 25 Sep 2026.
◆ ◆ The Wire takeaway
You now face a new market opened by ISEMBYLD's FDA approval alongside existing SMA treatments. Move quickly to build payer access and real world delivery to secure early commercial momentum and soften launch costs.
◆ Coverage
11 sources · first reported 12 Sep 2026 · latest 25 Sep 2026
◆ Topics